{
    "symbol": "IPHA",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-14 11:08:05",
    "content": " As mentioned, based on the AstraZeneca sponsored Phase II COAST data, AstraZeneca commenced PACIFIC-9, a Phase III trial evaluating the combination of either monalizumab or oleclumab plus durvalumab in the unresectable Stage III non-small cell lung cancer setting that had not progressed after concurring chemo radiation therapy. So when we look at the -- for your first question about the data readouts in the second half of 2022, the Sezary syndrome would be the first time that we're presenting that data, so that would be preliminary data on the Sezary syndrome pivotal cohort."
}